FDA Recommends Double Dosage of ‘Evusheld’ for Immunocompromised People

On Thursday, the FDA revised the emergency use authorization for ‘Evusheld’. ‘Evusheld’ is a monoclonal antibody against Covid-19 for immunocompromised people and those who cannot be vaccinated for medical reasons. The agency now recommends to double the initial dose and people who’ve already received the drug should go back for an additional dose as soon as possible. The FDA said “based on the most recent information and data available, Evusheld may be less active against certain omicron sub-variants. The dosing regimen was revised because available data indicates that a higher dose of the treatment may be more likely to prevent infection by Covid-19 omicron subvariants BA.1 and BA.1.1 than the originally authorized dose.” ‘Evusheld’ was granted Emergency Use Authorization on December 8th.